Cargando…

Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension

Background: Pulmonary hypertension (PH) is a devastating and progressive disease characterized by excessive proliferation of pulmonary artery smooth muscle cells (PASMCs) and remodeling of the lung vasculature. Adenosine signaling through the ADORA2B receptor has previously been implicated in diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Mertens, Tinne C. J., Hanmandlu, Ankit, Tu, Ly, Phan, Carole, Collum, Scott D., Chen, Ning-Yuan, Weng, Tingting, Davies, Jonathan, Liu, Chen, Eltzschig, Holger K., Jyothula, Soma S. K., Rajagopal, Keshava, Xia, Yang, Guha, Ashrith, Bruckner, Brian A., Blackburn, Michael R., Guignabert, Christophe, Karmouty-Quintana, Harry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992271/
https://www.ncbi.nlm.nih.gov/pubmed/29910735
http://dx.doi.org/10.3389/fphys.2018.00555
_version_ 1783329986844819456
author Mertens, Tinne C. J.
Hanmandlu, Ankit
Tu, Ly
Phan, Carole
Collum, Scott D.
Chen, Ning-Yuan
Weng, Tingting
Davies, Jonathan
Liu, Chen
Eltzschig, Holger K.
Jyothula, Soma S. K.
Rajagopal, Keshava
Xia, Yang
Guha, Ashrith
Bruckner, Brian A.
Blackburn, Michael R.
Guignabert, Christophe
Karmouty-Quintana, Harry
author_facet Mertens, Tinne C. J.
Hanmandlu, Ankit
Tu, Ly
Phan, Carole
Collum, Scott D.
Chen, Ning-Yuan
Weng, Tingting
Davies, Jonathan
Liu, Chen
Eltzschig, Holger K.
Jyothula, Soma S. K.
Rajagopal, Keshava
Xia, Yang
Guha, Ashrith
Bruckner, Brian A.
Blackburn, Michael R.
Guignabert, Christophe
Karmouty-Quintana, Harry
author_sort Mertens, Tinne C. J.
collection PubMed
description Background: Pulmonary hypertension (PH) is a devastating and progressive disease characterized by excessive proliferation of pulmonary artery smooth muscle cells (PASMCs) and remodeling of the lung vasculature. Adenosine signaling through the ADORA2B receptor has previously been implicated in disease progression and tissue remodeling in chronic lung disease. In experimental models of PH associated with chronic lung injury, pharmacological or genetic inhibition of ADORA2B improved markers of chronic lung injury and hallmarks of PH. However, the contribution of ADORA2B expression in the PASMC was not fully evaluated. Hypothesis: We hypothesized that adenosine signaling through the ADORA2B receptor in PASMC mediates the development of PH. Methods: PASMCs from controls and patients with idiopathic pulmonary arterial hypertension (iPAH) were characterized for expression levels of all adenosine receptors. Next, we evaluated the development of PH in ADORA2B(f/f)-Transgelin (Tagln)(cre) mice. These mice or adequate controls were exposed to a combination of SUGEN (SU5416, 20 mg/kg/b.w. IP) and hypoxia (10% O(2)) for 28 days (HX-SU) or to chronic low doses of bleomycin (BLM, 0.035U/kg/b.w. IP). Cardiovascular readouts including right ventricle systolic pressures (RVSPs), Fulton indices and vascular remodeling were determined. Using PASMCs we identified ADORA2B-dependent mediators involved in vascular remodeling. These mediators: IL-6, hyaluronan synthase 2 (HAS2) and tissue transglutaminase (Tgm2) were determined by RT-PCR and validated in our HX-SU and BLM models. Results: Increased levels of ADORA2B were observed in PASMC from iPAH patients. ADORA2B(f/f)-Tagln(cre) mice were protected from the development of PH following HX-SU or BLM exposure. In the BLM model of PH, ADORA2B(f/f)- Tagln(cre) mice were not protected from the development of fibrosis. Increased expression of IL-6, HAS2 and Tgm2 was observed in PASMC in an ADORA2B-dependent manner. These mediators were also reduced in ADORA2B(f/f)- Tagln(cre) mice exposed to HX-SU or BLM. Conclusions: Our studies revealed ADORA2B-dependent increased levels of IL-6, hyaluronan and Tgm2 in PASMC, consistent with reduced levels in ADORA2B(f/f)- Tagln(cre) mice exposed to HX-SU or BLM. Taken together, our data indicates that ADORA2B on PASMC mediates the development of PH through the induction of IL-6, hyaluronan and Tgm2. These studies point at ADORA2B as a therapeutic target to treat PH.
format Online
Article
Text
id pubmed-5992271
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59922712018-06-15 Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension Mertens, Tinne C. J. Hanmandlu, Ankit Tu, Ly Phan, Carole Collum, Scott D. Chen, Ning-Yuan Weng, Tingting Davies, Jonathan Liu, Chen Eltzschig, Holger K. Jyothula, Soma S. K. Rajagopal, Keshava Xia, Yang Guha, Ashrith Bruckner, Brian A. Blackburn, Michael R. Guignabert, Christophe Karmouty-Quintana, Harry Front Physiol Physiology Background: Pulmonary hypertension (PH) is a devastating and progressive disease characterized by excessive proliferation of pulmonary artery smooth muscle cells (PASMCs) and remodeling of the lung vasculature. Adenosine signaling through the ADORA2B receptor has previously been implicated in disease progression and tissue remodeling in chronic lung disease. In experimental models of PH associated with chronic lung injury, pharmacological or genetic inhibition of ADORA2B improved markers of chronic lung injury and hallmarks of PH. However, the contribution of ADORA2B expression in the PASMC was not fully evaluated. Hypothesis: We hypothesized that adenosine signaling through the ADORA2B receptor in PASMC mediates the development of PH. Methods: PASMCs from controls and patients with idiopathic pulmonary arterial hypertension (iPAH) were characterized for expression levels of all adenosine receptors. Next, we evaluated the development of PH in ADORA2B(f/f)-Transgelin (Tagln)(cre) mice. These mice or adequate controls were exposed to a combination of SUGEN (SU5416, 20 mg/kg/b.w. IP) and hypoxia (10% O(2)) for 28 days (HX-SU) or to chronic low doses of bleomycin (BLM, 0.035U/kg/b.w. IP). Cardiovascular readouts including right ventricle systolic pressures (RVSPs), Fulton indices and vascular remodeling were determined. Using PASMCs we identified ADORA2B-dependent mediators involved in vascular remodeling. These mediators: IL-6, hyaluronan synthase 2 (HAS2) and tissue transglutaminase (Tgm2) were determined by RT-PCR and validated in our HX-SU and BLM models. Results: Increased levels of ADORA2B were observed in PASMC from iPAH patients. ADORA2B(f/f)-Tagln(cre) mice were protected from the development of PH following HX-SU or BLM exposure. In the BLM model of PH, ADORA2B(f/f)- Tagln(cre) mice were not protected from the development of fibrosis. Increased expression of IL-6, HAS2 and Tgm2 was observed in PASMC in an ADORA2B-dependent manner. These mediators were also reduced in ADORA2B(f/f)- Tagln(cre) mice exposed to HX-SU or BLM. Conclusions: Our studies revealed ADORA2B-dependent increased levels of IL-6, hyaluronan and Tgm2 in PASMC, consistent with reduced levels in ADORA2B(f/f)- Tagln(cre) mice exposed to HX-SU or BLM. Taken together, our data indicates that ADORA2B on PASMC mediates the development of PH through the induction of IL-6, hyaluronan and Tgm2. These studies point at ADORA2B as a therapeutic target to treat PH. Frontiers Media S.A. 2018-06-01 /pmc/articles/PMC5992271/ /pubmed/29910735 http://dx.doi.org/10.3389/fphys.2018.00555 Text en Copyright © 2018 Mertens, Hanmandlu, Tu, Phan, Collum, Chen, Weng, Davies, Liu, Eltzschig, Jyothula, Rajagopal, Xia, Guha, Bruckner, Blackburn, Guignabert and Karmouty-Quintana. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Mertens, Tinne C. J.
Hanmandlu, Ankit
Tu, Ly
Phan, Carole
Collum, Scott D.
Chen, Ning-Yuan
Weng, Tingting
Davies, Jonathan
Liu, Chen
Eltzschig, Holger K.
Jyothula, Soma S. K.
Rajagopal, Keshava
Xia, Yang
Guha, Ashrith
Bruckner, Brian A.
Blackburn, Michael R.
Guignabert, Christophe
Karmouty-Quintana, Harry
Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension
title Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension
title_full Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension
title_fullStr Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension
title_full_unstemmed Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension
title_short Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension
title_sort switching-off adora2b in vascular smooth muscle cells halts the development of pulmonary hypertension
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992271/
https://www.ncbi.nlm.nih.gov/pubmed/29910735
http://dx.doi.org/10.3389/fphys.2018.00555
work_keys_str_mv AT mertenstinnecj switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT hanmandluankit switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT tuly switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT phancarole switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT collumscottd switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT chenningyuan switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT wengtingting switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT daviesjonathan switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT liuchen switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT eltzschigholgerk switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT jyothulasomask switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT rajagopalkeshava switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT xiayang switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT guhaashrith switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT brucknerbriana switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT blackburnmichaelr switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT guignabertchristophe switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension
AT karmoutyquintanaharry switchingoffadora2binvascularsmoothmusclecellshaltsthedevelopmentofpulmonaryhypertension